PKCα inhibitors promote breast cancer immune evasion by maintaining PD-L1 stability.
Yu J, Xiang Y, Gao Y, Chang S, Kong R, Lv X, Yu J, Jin Y, Li C, Ma Y, Wang Z, Zhou J, Yuan H, Shang S, Hua F, Zhang X, Cui B, Li P.
Yu J, et al. Among authors: cui b.
Acta Pharm Sin B. 2024 Oct;14(10):4378-4395. doi: 10.1016/j.apsb.2024.08.003. Epub 2024 Aug 8.
Acta Pharm Sin B. 2024.
PMID: 39525583
Free PMC article.